Deepa Jewellers and Cotec Healthcare Secure SEBI Approval for Upcoming IPOs

Why It Matters

The IPOs provide capital for Deepa to scale its B2B gold‑jewellery processing network and for Cotec to expand its CDMO capabilities, signaling strong investor appetite for diversified Indian manufacturing assets. Their listings also underscore the broader resurgence of large‑cap offerings in a market seeking growth beyond tech.

Key Takeaways

• Deepa Jewellers seeks ~₹250 cr ($30 m) via fresh issue and promoter sale
• IPO includes 1.18 cr shares offered by founders Ashish and Seema Agarwal
• Cotec Healthcare's CDMO IPO targets expansion of 4 bn‑unit capacity
• Both listings reflect robust primary‑market demand in jewellery and pharma sectors
• Deepa serves 315 B2B clients across 13 states, emphasizing wholesale processing

Pulse Analysis

The Securities and Exchange Board of India’s green light for Deepa Jewellers and Cotec Healthcare highlights a renewed vigor in the country’s primary‑equity market. After a period dominated by tech listings, investors are now gravitating toward asset‑heavy businesses that promise steady cash flows and tangible growth. Deepa’s dual‑track offering—combining a fresh issue with a promoter‑led sale—illustrates a strategic move to broaden its capital base while allowing early backers to monetize a portion of their holdings. Meanwhile, Cotec’s IPO aligns with the surge in demand for contract manufacturing services as global pharma firms seek cost‑effective production partners.

Deepa Jewellers operates a B2B hallmarked‑gold processing model that supplies traditional South Indian designs to over 315 wholesale clients across 13 states. By leveraging an outsourced manufacturing network of around 40 karigars, the firm maintains low overhead while scaling output. The infusion of roughly $30 million will likely fund capacity upgrades, technology adoption such as CNC cutting, and expansion into adjacent product lines like silver and 18‑20 karat pieces. This capital boost positions Deepa to capture a larger share of India’s burgeoning gold‑jewellery market, which is projected to grow alongside rising disposable incomes and festive demand.

Cotec Healthcare’s CDMO platform, with a 4 billion‑unit capacity spread across 24 dosage forms, serves both domestic manufacturers and export markets in 14 countries. The pharma sector’s post‑pandemic emphasis on diversified supply chains has heightened the value of contract manufacturers capable of rapid scale‑up. Proceeds from the IPO are expected to expand its Roorkee facility, invest in advanced aseptic lines, and broaden its therapeutic portfolio, especially in high‑margin segments like injectables and specialty drugs. For investors, Cotec offers exposure to a resilient segment of the healthcare value chain, where steady regulatory demand and export opportunities can translate into consistent earnings growth.

Deal Summary

Deepa Jewellers, a B2B hallmarked gold jewellery processor, and Cotec Healthcare, a pharmaceutical CDMO, have received final SEBI approval to launch their IPOs. Deepa plans to raise up to Rs 250 crore (~$30 million) via a fresh issue and offer‑for‑sale, while Cotec's IPO details remain undisclosed. The approvals pave the way for both companies to list on Indian stock exchanges.